# TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium

> **NCT00077688** · PHASE2 · COMPLETED · sponsor: **Achieve Life Sciences** · enrollment: 44 (—)

## Conditions studied

- Bladder Neoplasms
- Ureteral Neoplasms
- Urethral Neoplasms
- Carcinoma, Transitional Cell

## Interventions

- **DRUG:** TOCOSOL Paclitaxel

## Key facts

- **NCT ID:** NCT00077688
- **Lead sponsor:** Achieve Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** —
- **Final completion:** 2007-09
- **Target enrollment:** 44 (—)
- **Last updated:** 2009-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00077688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00077688, "TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00077688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*